Skip to Content

Frequently asked questions.

Do you want to know something about Almirall? These are the questions people most often ask of us.


1.- Who is Almirall?

Almirall is a leading skin-health focused global pharmaceutical company based in Barcelona that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations Our efforts are focused on fighting skin health diseases and helping people feel their best. We support healthcare professionals in continuous improvement, bringing our innovative solutions where they are needed.


2.- What is Almirall's purpose?

Our Nobel Purpose, “Transform the patients’ world by helping them realize their hopes & dreams for a healthy life”, reflects our reason why and our essence today and for future generations. This purpose transmits our goal to make our patient’s life better, our focus on their wellbeing. It is our footprint, our legacy for future generations, and our contribution to society.

In terms of strategic direction, we want to focus our resources in:

  • Double down on medical derma, focusing on patient sub-populations, to address granular unmet needs.

  • Capturing value through real differentiation.

  • BD and R&D efforts targeting breakthrough innovation, with significant external collaboration.

  • “Play to win”, investing in launch, M&A and capability building to maximize chances of success with an execution- focused culture.


3.- How many countries are Almirall's medicines available in?

Almirall's medicinal products are marketed in over 70 countries on the five continents.


4.- Where are its affiliates?

In Spain, Belgium-Luxembourg, Portugal, France, Italy, Germany, Austria, Poland, Switzerland, United Kingdom&Ireland, Nordic Countries, The Netherlands and United States. Almirall has direct presence in 21 countries through 13 affiliates.


5.- What were Almirall's total revenues & net sales in 2018?

Total revenues in 2018 were €811.00 million, while net sales totalled €756.9 million.


6.- What percentage of Almirall's net sales comes from proprietary drugs?

Proprietary research & development drugs represent 70,6% of Almirall's net sales in 2018.


7.- Which therapeutic areas does Almirall mainly focus its R&D on?

At Almirall, we have identified the following four core therapeutic indications as those with the most potential for growth for our business: actinic keratosis, atopic dermatitis, psoriasis, and acne.


8.- What proportion of its budget does Almirall allot to research and development?

Almirall devotes around 12% of its net sales and 15% of its workforce to R&D (2018).


9.- What are Almirall's medicines?

Almirall's top-selling brands of 2018 accounted for over 49% of net sales, which reflects a balanced portfolio without over-exposure to a single product. Out of the top-selling drugs, seven were proprietary products: Ebastel®, Ciclopoli®, Almax®, Decoderm®, Aczone®, Airtal® and Skilarence.


10.- What is the size of Almirall's overall workforce?

In 2018, our workforce numbered around 1,800 people. Of these, 269 work in R&D.


11.- What are Almirall's most important R&D centres?

Almirall has built and acquired the infrastructure needed to succeed in innovation. The company has two full R&D centres in Europe: The Research and Development Centre in Sant Feliu de Llobregat (Barcelona) and the R&D Centre in Reinbeck (Germany), and one more in Exton, Pennsylvania (US), dedicated to clinical and regulatory activities.